3187.0: Monday, November 17, 2003: 12:30 PM-2:00 PM | |||
Oral | |||
| |||
| Although the WHO declared smallpox globally eradicated in 1980, there is concern that smallpox may be used for bioterrorism. Surveillance is a key component of smallpox preparedness and response at the national, state and local levels of the public health system. Since January 2002, the CDC has assisted state/local health departments in conducting enhanced surveillance for rash illnesses suspected of smallpox. CDC established a consultation line 24 hours per day and 7 days a week. As of April 23, 2003, 11 suspected cases have been reported. All were low risk for smallpox with a diagnosis of either chickenpox (varicella), a drug or allergic reaction, herpes simplex virus type 1 infection, and an atypical cutaneous infection. A civilian smallpox vaccination program of medical and public health workers (first reponders) began in the United States in January 2003, because routine civilian vaccination ceased in 1972. As of April 18, 2003, smallpox vaccine was administered to 33,444 civilian personnel in 54 jurisdictions. As of April 18, 10 suspected or probable cases of myopericarditis, 6 cases of acute myocardial infarction (MI), 1 confirmed case of generalized vaccinia, 2 confirmed cases of inadvertent inoculation (nonocular), and 1 confirmed case of ocular inoculation were reported. While a causal association between vaccine and adverse cardiac events is unproven, as a precaution, the ACIP now recommends that persons with physician-diagnosed cardiac disease and risk factors be excluded from vaccination during this program. This special session will discuss surveillance of smallpox and of adverse reactions to smallpox vaccine (vaccinia), update current recommendations for preparedness and response, and highlight future surveillance. | |||
| Learning Objectives: 1. Describe the historical and contemporary aspects of smallpox surveillance in the United States. 2. Discuss smallpox preparedness and response in the United States and the role of surveillance. 3. Describe Federal and State Preparedness and Response plans. 4. Discuss the components and methods for pre-event and post-event surveillance at the local, state, and federal levels of government, including a key component of pre-event surveillance (the CDC protocol for evaluating patients for smallpox). 5. Describe the types of suspected cases of smallpox at the local, state, and federal levels of government. 5. Discuss components and methods of adverse event surveillance and adverse reactions to smallpox vaccine during the pre-event vaccination program of civilians (first responders). | |||
| See individual abstracts for presenting author's disclosure statement and author's information. | |||
| Sonja Hutchins, MD, MPH, DrPH | |||
| Historical Perspective: Mike Lane, MD | |||
| Overview of Smallpox Preparedness and Response Raymond Strikas, Mehran Massoudi, PhD | |||
| Federal and State Smallpox Preparedness and Response Plans Joanne Cono, MD, ScM | |||
| Smallpox Disease Surveillance--United States, 2002-2003 Sonja Hutchins, MD, MPH, DrPH, Mona Marin, MD, Jane Seward, MBBS, MPH, Inger Damon, MD, PhD, CDC Rash Illness Team | |||
| Smallpox Vaccine Safety Surveillance John Iskander, MD, MPH | |||
| State Perspectives on Surveillance of Smallpox and Surveillance of Smallpox Vaccination Adverse Events Celia Woodfill, PhD | |||
| Qs and As | |||
| Organized by: | Epidemiology | ||
| CE Credits: | CME, Health Education (CHES), Nursing, Pharmacy | ||